Sources Sought: Functional Omics Core Laboratory Services

Event Organizer: National Institutes of Health

Event Website: https://sam.gov/opp/58cee168112b444fa1443522dbdc8083/view

Event Overview:

Solicitation #: SBSS75N93023R00013

“The mission of the Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health (NIH) is to ensure an end to the human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) epidemic by supporting research that can lead to the development of therapies, vaccines, and prevention strategies … The purpose of the Functional Omics Core Laboratory (FOCL) is to provide high quality assessment of the immunogenicity and efficacy of vaccines or other prevention strategies, and generate omics signatures of genes, epigenome, transcriptomes, and proteins to identify biomolecules expression and pathway profiles that could define correlates of protection and predict vaccine efficacy for HIV and other infectious diseases. Assays may be performed on fresh and/or frozen preclinical samples. All assays undergo testing for interand intra-assay as well as inter- and intra operator variability. Standard operating procedures (SOPs) are developed for all assays, laboratory processes, and equipment use and maintenance … The Contractor shall conduct, develop, acquire, improve, implement, validate, analyze and report data from state-of-the-art high-throughput functional omics assays (e.g., bulk, single-cell, and spatial RNA-seq, ATAC-seq and CITE-seq) and approaches (e.g., genomics, epigenomics, transcriptomics, and proteomics) for comprehensive characterization of immune responses in samples from in vivo or in vitro studies investigating simian immunodeficiency virus (SIV), simian-human immunodeficiency virus (SHIV), HIV and other infectious diseases. The assays will primarily focus on samples from animal models for HIV, however analysis of samples from human clinical trials with HIV or other infectious diseases maybe included to evaluate immunogenicity and efficacy of vaccines or other prevention strategies, as directed by the COR.”

Due date: 18 September 2023, 3:00 p.m. EDT